{"id":479552,"date":"2021-04-21T08:20:16","date_gmt":"2021-04-21T12:20:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/"},"modified":"2021-04-21T08:20:16","modified_gmt":"2021-04-21T12:20:16","slug":"investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/","title":{"rendered":"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc."},"content":{"rendered":"<div class=\"mw_release\">\n<p>LOS ANGELES, April  21, 2021  (GLOBE NEWSWIRE) &#8212; via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0SdaFenR2ylR5nBqiNr2jnrApGgnkmZw0BNRj3buFmRH5g9bd4aSqcKa7x2SEPzhiVdir50OyMT4QoBv3942SQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>InvestorWire<\/u><\/a><u> &#8212;<\/u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0SdaFenR2ylR5nBqiNr2jt_AaJcQlNN48_B5I1dt-wEHcIUK0E5_rBJneOXTxS62FqIXBRtR48fSEqLnymjHyxkXNWclbKdR2-Drjm5JRSs=\" rel=\"nofollow noopener\" target=\"_blank\"><u>InvestorBrandNetwork<\/u><\/a>\u00a0(\u201cIBN\u201d), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dLmUgaRyR5bNKDsuyZC2_t_qL4sEtiVqAHKksM6JJwk0UCMxCYJn4gxdsWdx84mPMhwQa_-KTIE4-le4zTwlhQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>The <\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d8FTZBgnk1PqvSSfGfuA68793-p0uhaPdubOLks3L_OUXdQdkhoVN5zdypL8qyh9q0W2jMCwuZ6aaeXqLGWH6Q==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Bell2Bell<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CSBaq3ZUWt42eoSJjSJ0Hrte-lnQ6x1E9Nul5Avf6vAnQbGqCUiVQvikpqXDpSjT6_p1cxN38_qkHkRZAXSGGg==\" rel=\"nofollow noopener\" target=\"_blank\"><u> Podcast<\/u><\/a> as part of its sustained effort to provide specialized content distribution via widespread syndication channels.<\/p>\n<p>The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell\u2019s latest podcast features Mel Engle, newly appointed CEO of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fY2lFM7PtqTgkfG2YS1-V8NTZbJBnHwNqFubi1GbPVmpO64rytDCLfHCjdhwNhzrbJYM2p4fZqvia18rmJimOnBxYAEaFujg8IE3pkpLiWZDWbwjfli1_h5dSU5RHjCx_2jRpsMDPzQw6qNKUg14x0thI3JZck3i9kpTD2xwGWk=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Predictive Oncology Inc. (NASDAQ: POAI)<\/u><\/a>, as well as CFO Bob Myers and Mark Collins, Chief Technical Officer of the company\u2019s Helomics subsidiary. During the briefing, Engle discussed his background before passing the microphone to Myers and Collins for updates on Predictive Oncology\u2019s financial footing, current operations and goals for 2021.<\/p>\n<p>\u201cI\u2019ve been on the board of Predictive Oncology for about four years, and, within the last year-and-a-half, I\u2019ve been the Chairman of the Board,\u201d Engle said. \u201cBeing in that kind of position, it\u2019s easier for me to be able to step into this role. \u2026 I\u2019ve been a CEO of many companies beforehand, the most notable of which is a pharmaceutical company that was called Dey Laboratories, which was a subsidiary of Merck. We were a $610 million company when sold to Mylan back in 2007. That was a pharmaceutical respiratory company, so I\u2019m very familiar with the ins-and-outs of R&amp;D and the notion of what Predictive Oncology is doing.\u201d<\/p>\n<p>Engle is also currently on the board of WindGap Medical, a startup focused on the development of an innovative EpiPen, and he previously served as CEO of cell separation company ThermoGenesis and orthobiologics firm Anika Therapeutics.<\/p>\n<p>To hear the entire podcast and subscribe for future episodes, visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pHpCCXzxj0jAy0vbHoL4UjI2jv1D3fbfbgNjS4lN4tVknBxRsjDuB3c535Vv6AxF2v_6f1hb9R-raHZkjjcmxlOmLLDmJZy5ggDIQZpdgYryBdhYMv7yZYvQpZx9-BQr\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/podcast.bell2bell.com<\/u><\/a>.<\/p>\n<p>Next, CFO Bob Myers discussed Predictive Oncology\u2019s current financial standing.<\/p>\n<p>\u201cWe are in a great situation, probably the best situation that we\u2019ve been in since the existence of the company in terms of our cash capability and the strength of our balance sheet,\u201d Myers noted. \u201cWe have absolutely no liabilities other than your normal accounts payable, which are quite low. We have a lot of things going on in terms of the income that we expect to get this year and the projects that we have. I think that we are going into these projects in a strong position.\u201d<\/p>\n<p>Mark Collins then stepped into the spotlight to provide an update on all things Helomics.<\/p>\n<p>\u201cFrom Helomics\u2019 perspective, possibly the most important thing that we\u2019ve announced and are working on is our platform that brings together Helomics\u2019 assets (a translatable assay, data on 150,000 patient tumor samples and a machine learning platform licensed from Carnegie Mellon University) as a fee-for-service platform for pharmaceutical companies to test their drugs against our cancer cell lines,\u201d Collins added. \u201cIn addition, we also kicked off, at the beginning of this year, an internal drug repositioning project where we\u2019re actually testing some known anti-cancer drugs against our patient cell lines, driven by the machine learning. We expect that to generate some proof data for the platform which informs the commercial discussion but also to generate some valuable intellectual property about those compounds and their activity against specific patient profiles.\u201d<\/p>\n<p>Join InvestorBrandNetwork\u2019s Stuart Smith and three key executives from the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fY2lFM7PtqTgkfG2YS1-V8NTZbJBnHwNqFubi1GbPVmpO64rytDCLfHCjdhwNhzrPVnGqXZkhSLcaOVClPB407PBIG5NfPirXPDtlKLL8S69TDzRUUKMXmJsD-Rsjkb1PT0F2uR7SVigEGs2j-4uJ9iCtvCDtKeZKs6db9VSmtg=\" rel=\"nofollow noopener\" target=\"_blank\"><u>Predictive Oncology Inc. (NASDAQ: POAI)<\/u><\/a> team to learn more about Predictive Oncology\u2019s current operations and its goals for the balance of 2021 and beyond.<\/p>\n<p>To hear the episode and subscribe for future podcasts, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pHpCCXzxj0jAy0vbHoL4UjI2jv1D3fbfbgNjS4lN4tVYohWKBwn-RN1AewP6SXlD-gB4Q6Auage614XvDx-j8qigOxRj-VeKz2eUXo_1WJqIid42wgBmnIMicbwkLfs6\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/podcast.bell2bell.com<\/u><\/a>.<\/p>\n<p>The latest installment of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=j8n5VxxGSk80Z2jimXqFS9X0VMWcDwLO9H6rCz6WdmMHmb0BCgbEZfjKMyfwRrmNuUV5HsnSes7_hyuErMY3XQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>The <\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=d8FTZBgnk1PqvSSfGfuA6z7re3uKn9rbzrLEHsY9OSCsjlCj6GRc0BqOctHlQC56yfDu0nl1YDYsXDKyUhDoKQ==\" rel=\"nofollow noopener\" target=\"_blank\"><u>Bell2Bell<\/u><\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CSBaq3ZUWt42eoSJjSJ0HkGITryXu9m6Y-h0lgi8U5kUXUrNAV8NcWWfJX1JvS1ILHE7n-qPs-nCQUpTCpvpfw==\" rel=\"nofollow noopener\" target=\"_blank\"><u> Podcast<\/u><\/a> continues to reinforce InvestorBrandNetwork\u2019s commitment to the expansion of its robust network of brands, client partners, followers and the growing <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=afZ3VRIIP1IQCHj0JbNJiZMIHXZRLcrHKtUFCbJ3htXXpd79HWxFJpsgn47cbr6jUCO5K_Fwe9CdyX_ExT4-EvPUm4Vt2o-TohSr72xW9w3JU69tc-4lctihJODFJZ37lEYo5pewKQDThDQ1n0pbTJkxPg24lXVYzjD0ma-z-O4=\" rel=\"nofollow noopener\" target=\"_blank\"><u>IBN Podcast Series<\/u><\/a>. For more than 15 years, IBN has leveraged this commitment to provide unparalleled distribution and corporate messaging solutions to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_s5qwiQiauAqP21hjDmIOzMo8h8tXm2ijjYdG2GQnjHB_yq2tp0oB3GubK7bMI74Sb_8ZnCVRSPmEtOT3lX84Z9a0fqjnrsmJVvX6XTa6AdKrH_9bZUoWRobOOfTB-3l3_E3FrLT9CJbIOwM7G48kg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>500+ public and private companies<\/u><\/a>.<\/p>\n<p>To learn more about IBN\u2019s achievements and milestones via a visual timeline, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pHpCCXzxj0jAy0vbHoL4UhJd_9xVzKRkl7MqNi76VP5TP1f485iiutjOk8bK5Xx13g_pUTTeCsA1ljRxj9CirY9GTvnBTj3GsFHfNPmTb6Q=\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/IBN.fm\/TimeLine<\/u><\/a><\/p>\n<p>\n        <strong>About InvestorBrandNetwork<\/strong>\n      <\/p>\n<p>The\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0SdaFenR2ylR5nBqiNr2jr_rftRAE5dOmLLznHRNKdHluX_0TjHOdThH6Y9z3e1ELnqkENUFahg06sPEMGx-qvCaw-8htYViQipFQH82BxJ3Gl6NZC2UU-jtzgc4VCAM\" rel=\"nofollow noopener\" target=\"_blank\"><u>InvestorBrandNetwork<\/u><\/a>\u00a0(\u201cIBN\u201d) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.<\/p>\n<p>Through\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mgnu7ykGU8Qo-ZXmgpmcSzpQHPe2qHyZIM6Gd8TqoBoN9jLloiprOlbafaN2RX8Fah8fLwY4yKODYSc4WBOJREKegqiJRjvTk467N1DULLU=\" rel=\"nofollow noopener\" target=\"_blank\"><u>NetworkNewsWire<\/u><\/a>\u00a0(\u201cNNW\u201d) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0SdaFenR2ylR5nBqiNr2juMrCD5m9qi5ZfiXRtbub2YxjQryka_7YZtz00mVy5oVeRgcNOFgYFYaKe4Y8df1Q9nraSLTtoFHApjXL4sV2gY=\" rel=\"nofollow noopener\" target=\"_blank\"><u>InvestorWire<\/u><\/a>\u00a0to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.<\/p>\n<p>For more information on IBN, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pHpCCXzxj0jAy0vbHoL4UuSC7YIc-_MlF1aLol8WC9cUz0rjX4FtgxL0citSIbaq308tPmTCmPeIo-mt-w_-78g43k0cZkalblXxRwALfFAM9FVgwuZYlK8V56lP6OivWBC-54mqeEnzvxUt0oSBEg==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/www.InvestorBrandNetwork.com<\/u><\/a>.<\/p>\n<p>Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=pHpCCXzxj0jAy0vbHoL4UtcMOT-HluE831kLi5y0-S4CNFqEcJtL_viHWgD6TsXZcQUVSVbBlFyAPsFNbGIgu2_ff7trE8MB9Bg_IlRM_K4=\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/IBN.fm\/Disclaimer<\/u><\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company&#8217;s SEC filings. These risks and uncertainties could cause the company&#8217;s actual results to differ materially from those indicated in the forward-looking statements.<\/p>\n<p>\n        <strong>Corporate Communications<\/strong>\n      <\/p>\n<p>InvestorBrandNetwork (IBN)<br \/> Los Angeles, California<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rXP6vjahWSmpXtR20eosUbXQZ9ogRPiZ9goVeIfNJrQA4mV0cgZlRlKr9dd2Pn-Lg3m8vU-cTM6XqDh1pjQ2NgDYC0cP9qSp8vee_1rwU4tpIYKkRBo1rEP5xG4aWjsE\" rel=\"nofollow noopener\" target=\"_blank\"><u>www.InvestorBrandNetwork.com<\/u><\/a><br \/> 310.299.1717 Office<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=YvBYebTIAJtmeubr0Ti9oL-9Xuy0ftzOhCA0dx48byJsmdyO_zPv7OJzQ7hrAxJDpwIrcT82sHHTkdbxAPIvurwDeEZg7oGDesrVhOOESzc59ogLgiYExc3uvwCHf8Fm\" rel=\"nofollow noopener\" target=\"_blank\"><u>Editor@InvestorBrandNetwork.com<\/u><\/a><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8ea28969-fe28-4746-8e4c-cc45c3f276a9\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOS ANGELES, April 21, 2021 (GLOBE NEWSWIRE) &#8212; via InvestorWire &#8212;InvestorBrandNetwork\u00a0(\u201cIBN\u201d), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of\u00a0The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell\u2019s latest podcast features Mel Engle, newly appointed CEO of Predictive Oncology Inc. (NASDAQ: POAI), as well as CFO Bob Myers and Mark Collins, Chief Technical Officer of the company\u2019s Helomics subsidiary. During the briefing, Engle discussed his background before passing the microphone to Myers and Collins for updates on Predictive Oncology\u2019s financial &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc.&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-479552","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc. - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc. - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, April 21, 2021 (GLOBE NEWSWIRE) &#8212; via InvestorWire &#8212;InvestorBrandNetwork\u00a0(\u201cIBN\u201d), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of\u00a0The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell\u2019s latest podcast features Mel Engle, newly appointed CEO of Predictive Oncology Inc. (NASDAQ: POAI), as well as CFO Bob Myers and Mark Collins, Chief Technical Officer of the company\u2019s Helomics subsidiary. During the briefing, Engle discussed his background before passing the microphone to Myers and Collins for updates on Predictive Oncology\u2019s financial &hellip; Continue reading &quot;InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc.&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-21T12:20:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc.\",\"datePublished\":\"2021-04-21T12:20:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/\"},\"wordCount\":1007,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/\",\"name\":\"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc. - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk=\",\"datePublished\":\"2021-04-21T12:20:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc. - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/","og_locale":"en_US","og_type":"article","og_title":"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc. - Market Newsdesk","og_description":"LOS ANGELES, April 21, 2021 (GLOBE NEWSWIRE) &#8212; via InvestorWire &#8212;InvestorBrandNetwork\u00a0(\u201cIBN\u201d), a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of\u00a0The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bell2Bell\u2019s latest podcast features Mel Engle, newly appointed CEO of Predictive Oncology Inc. (NASDAQ: POAI), as well as CFO Bob Myers and Mark Collins, Chief Technical Officer of the company\u2019s Helomics subsidiary. During the briefing, Engle discussed his background before passing the microphone to Myers and Collins for updates on Predictive Oncology\u2019s financial &hellip; Continue reading \"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc.\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-21T12:20:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc.","datePublished":"2021-04-21T12:20:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/"},"wordCount":1007,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/","name":"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc. - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk=","datePublished":"2021-04-21T12:20:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODIxOTY0NSM0MTI4MzU3IzIwODg3OTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-ibn-announces-latest-episode-of-the-bell2bell-podcast-featuring-mel-engle-ceo-of-predictive-oncology-inc\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Mel Engle, CEO of Predictive Oncology Inc."}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479552","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=479552"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/479552\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=479552"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=479552"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=479552"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}